{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:14:27Z","timestamp":1794456867280,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"AstraZeneca Nordic-Baltic"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-016-1211-y","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T07:18:05Z","timestamp":1484637485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Factors associated with initiation and persistence of urate-lowering therapy"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-0968","authenticated-orcid":false,"given":"Mats","family":"Dehlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emin Hoxha","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Telg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart T. H.","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,17]]},"reference":[{"issue":"11","key":"1211_CR1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nrrheum.2014.124","volume":"10","author":"P Richette","year":"2014","unstructured":"Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654\u201361.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1211_CR2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1136\/annrheumdis-2012-202972","volume":"74","author":"L Grimaldi-Bensouda","year":"2015","unstructured":"Grimaldi-Bensouda L, Alperovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, Richette P, Group PGM. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2015;74(5):836\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1211_CR3","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3899\/jrheum.141542","volume":"42","author":"JH Chen","year":"2015","unstructured":"Chen JH, Lan JL, Cheng CF, Liang WM, Lin HY, Tsay GJ, Yeh WT, Pan WH. Effect of urate-lowering therapy on the risk of cardiovascular disease and all-cause mortality in patients with gout: a case-matched cohort study. J Rheumatol. 2015;42(9):1694\u2013701.","journal-title":"J Rheumatol"},{"issue":"1","key":"1211_CR4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/archinte.1955.00250070099012","volume":"95","author":"WP Boger","year":"1955","unstructured":"Boger WP, Strickland SC. Probenecid (benemid); its uses and side-effects in 2,502 patients. AMA Arch Intern Med. 1955;95(1):83\u201392.","journal-title":"AMA Arch Intern Med"},{"issue":"4","key":"1211_CR5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1211_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-015-0522-8","volume":"17","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, See LC, Yu KH, Luo SF, Zhang W, Doherty M. Epidemiology and management of gout in Taiwan: a nationwide population study. Arthritis Res Ther. 2015;17:13.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1211_CR7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/ard.2004.024091","volume":"64","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher Jr HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990\u20131999. Ann Rheum Dis. 2005;64(2):267\u201372.","journal-title":"Ann Rheum Dis"},{"key":"1211_CR8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1186\/s13075-016-1062-6","volume":"18","author":"M Dehlin","year":"2016","unstructured":"Dehlin M. Incidence and prevalence of gout in western Sweden. Arthritis Res Ther. 2016;18:1062\u20136.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1211_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"1211_CR10","unstructured":"Statistiska C: Folkm\u00e4ngden efter region, civilst\u00e5nd, \u00e5lder och k\u00f6n. \u00c5r 1968\u20132014 http:\/\/www.scb.se . 2012."},{"key":"1211_CR11","unstructured":"Ministry of Health and Social Affairs SGO: Updated high-cost protection \u2013 outpatient care and medication. Health and Social Affairs; 2011. https:\/\/www.socialstyrelsen.se\/Lists\/Artikelkatalog\/Attachments\/19238\/2013-12-1.pdf . Accessed 31 Dec 2012."},{"key":"1211_CR12","unstructured":"Socialstyrelsen: L\u00e4kemedelsregistret http:\/\/www.socialstyrelsen.se\/register\/halsodataregister\/lakemedelsregistret . Accessed 31 Dec 2012."},{"issue":"9","key":"1211_CR13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"1211_CR14","unstructured":"Act (2002:687) on Pharmaceutical Benefits e: (4 July 2002, 2002). Pharmaceutical Benefits; 2002. http:\/\/www.tlv.se\/Upload\/English\/ENG-ordinance-2002-687.pdf . Accessed 31 Dec 2012."},{"key":"1211_CR15","unstructured":"Kellgren JH, Jeffrey MR, Ball J. The epidemiology of chronic rheumatism. 1 vol. Oxford: Blackwell Scientific; 1963. p. 295-7."},{"key":"1211_CR16","first-page":"385","volume":"1968","author":"J Decker","year":"1968","unstructured":"Decker J. Report from the subcommittee on diagnostic criteria for gout. In: Bennett PH, Wood PHN, eds. Population studies of the rheumatic diseases. Proceedings of the Third International Symposium, New York, June 5\u201310, 1966. Amsterdam: Excerpta Medica Foundation. 1968;1968:385\u20137.","journal-title":"Amsterdam: Excerpta Medica Foundation"},{"issue":"3","key":"1211_CR17","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895\u2013900.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"1211_CR18","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3899\/jrheum.091385","volume":"37","author":"I Pelaez-Ballestas","year":"2010","unstructured":"Pelaez-Ballestas I, Hernandez Cuevas C, Burgos-Vargas R, Hernandez Roque L, Teran L, Espinoza J, Esquivel-Valerio JA, Goycochea-Robles MV, Aceves FJ, Bernard AG, et al. Diagnosis of chronic gout: evaluating the American College of Rheumatology proposal, European League Against Rheumatism recommendations, and clinical judgment. J Rheumatol. 2010;37(8):1743\u20138.","journal-title":"J Rheumatol"},{"issue":"13","key":"1211_CR19","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archinternmed.2010.196","volume":"170","author":"HJ Janssens","year":"2010","unstructured":"Janssens HJ, Fransen J, van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med. 2010;170(13):1120\u20136.","journal-title":"Arch Intern Med"},{"issue":"10","key":"1211_CR20","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, et al. 2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789\u201398.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1211_CR21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12891-015-0614-2","volume":"16","author":"M Dehlin","year":"2015","unstructured":"Dehlin M, Stasinopoulou K, Jacobsson L. Validity of gout diagnosis in Swedish primary and secondary care - a validation study. BMC Musculoskelet Disord. 2015;16(1):149.","journal-title":"BMC Musculoskelet Disord"},{"key":"1211_CR22","doi-asserted-by":"publisher","unstructured":"Drivelegka P, Jacobsson L, Sigurdardottir V, Sv\u00e4rd A, Dehlin M. Comorbidity pattern at the time of gout diagnosis: a population- and register-based case-control study from Western Sweden. Ann Rheum Dis. 2016;75(Suppl 2):381. doi: 10.1136\/annrheumdis-2016-eular.4934 .","DOI":"10.1136\/annrheumdis-2016-eular.4934"},{"issue":"24","key":"1211_CR23","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1001\/jama.2014.14484","volume":"312","author":"CF Kuo","year":"2014","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA. 2014;312(24):2684\u20136.","journal-title":"JAMA"},{"issue":"7","key":"1211_CR24","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00296-013-2935-5","volume":"34","author":"S Horsburgh","year":"2014","unstructured":"Horsburgh S, Norris P, Becket G, Arroll B, Crampton P, Cumming J, Keown S, Herbison P. Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int. 2014;34(7):963\u201370.","journal-title":"Rheumatol Int"},{"issue":"2","key":"1211_CR25","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","volume":"11","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther. 2009;11(2):R46.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1211_CR26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925\u201334.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"1211_CR27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437\u201343.","journal-title":"Pharmacotherapy"},{"key":"1211_CR28","doi-asserted-by":"crossref","unstructured":"Lavoie KL, Rash JA, Campbell TS. Changing provider behavior in the context of chronic disease management: focus on clinical inertia. Annu Rev Pharmacol Toxicol. 2016.","DOI":"10.1146\/annurev-pharmtox-010716-104952"},{"issue":"5","key":"1211_CR29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jbspin.2011.05.010","volume":"78","author":"G Reach","year":"2011","unstructured":"Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011;78(5):456\u20139.","journal-title":"Joint Bone Spine"},{"issue":"9","key":"1211_CR30","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","volume":"71","author":"K Spencer","year":"2012","unstructured":"Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71(9):1490\u20135.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-1211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T13:07:56Z","timestamp":1568725676000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-016-1211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,17]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-1211-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,17]]},"article-number":"6"}}